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Systemic Versus Intracoronary Streptokinase Infusion in the
Treatment of Acute Myocardial Infarction
ROLF SCHRODER, MD
Berlin. West Germany
Clinically encouraging results can be obtained with an
intravenous high dose short-time infusion of streptoki-
nase in patients with evolvingmyocardial infarction. The
feasibility and efficacy of the intracoronary and the sys-
temic approach of streptokinase therapy in acute myo-
cardial infarction are discussed in this report and include
topics such as infarct artery recanalization success rate,
coronary thrombus lysis time, benefit for patients with
New dimensions and perspectives of clinical interest emerged
since coronary angiography reestabli shed the importance of
coronary thrombosis as the major precipitating event in the
pathogenesis of acute myocardial infarction (I). Rapid
thrombolysis with attendant recanalization and reperfusion
was achieved with the use of intracoronary infusion of strep-
tokinase, thereby producing possible salutary results of sal-
vaging jeopardized ischemic myocardium, reducing infarct
size and improving left ventricular function (2-5). How-
ever, introducing this mode of therapy for all patients would
imply staffing an overwhelming number of catheterization
laboratories 24 hours a day, 7 days a week with appropri-
ately trained personnel. Therefore, the recent observation
that systemic infusion of streptokinase also rapidly lyses
coronary occluding thrombi in patients with acute myo-
cardial infarction calls for a reassessment of the intravenous
route as initial therapy (6-9).
In this report, recent data with high dose intravenous
short-time infusion are discussed, thereby comparing fea-
sibility and efficacy of the intracoronary and systemic ap-
proaches to streptokinase therapy in acute myocardial
infarction.
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subtotal coronary occlusion, reocclusion rate, the ne-
cessity of additional surgical interventions, salvage of
ischemic myocardium and side effects.
The value of high dose intravenous short-time strep-
tokinase infusion needs to be assessed with properly de-
signed clinical trials against the background afforded by
the results observed with direct intracoronary strepto-
kinase infusion.
Randomized Clinical Trials With Intravenous
Streptokinase Infusion
In 1959, Fletcher et al. ( 10) were the first to use an
intravenous streptokinase infusion in the treatment of acute
myocardial infarction . They suggested that patients may
derive clinical benefit from this treatment and gave consid-
erable assurance that certain theoretical objections that could
be raised against this mode of therapy were without practical
basis. Since 1959, 15 prospective randomized placebo con-
trolled clinical trials have been carried out. In most of the
trials, a loading dose of 250,000 IU streptokinase was fol-
lowed by an infusion of 100,000 IU/h for 12 to 24 hours
(11 ,12) . Despite these doses, bleeding complications were
no major problem as a cause of death , although they were
observed slightly more frequently than in the control group
(II) . Of the 2,467 patients treated with streptokinase in 12
multicenter studies, 6 patients died from bleeding compli-
cations related to the thrombolytic therapy (13). The rate
of cardiac rupture was found to be similar in both the treat-
ment and control groups . A true deleterious effect of throm-
bolytic treatment or a significant difference in favor of the
control group has never been reported (II).
Results of treatment within 12 hours. In Table 1, data
on the six trials in which intravenous streptokinase infusion
was initiated within 12 hours after onset of symptoms are
presented (6) . In five trials, a significant reduction in death
among treated patients as compared with untreated patients
was claimed. In four trials, the mortality rate in the control
group appeared to be relatively high ; however, at that time
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Table 1. Data From Six Prospective Randomized Trials With Intravenous Streptokinase (SK) Infusion Within 12 Hours After Onset
of Symptoms in Patients With Acute Myocardial Infarction
Trials Patients
Dose (IU)
Duration
Mortality (%)
Follow-up
(Ret) Year (n) Initial Per Hour (h) SK Control (days) Sigmficance
German-Swiss I 1966 558 250,000 166,000 18 14.1 21.7 40 P < 0.05
(14)
German-Swiss II 1971 269 250.000 137,000 18 14.5 260 40 P < 0.01
(15)
Italian (16) 1971 321 250.000 150,000 12 116 11.5 40 NS
Frankfort (17) 1973 206 250.000 200,000 3 12.8 27.6 40 P < 0.0 1
Austrian (18) 1977 728 500,000 110,000 20 10.5 17.3 40 P < 0.01
European 1979 315 250,000 100,000 24 \5.6 30.6 180 P < 0.01
Cooperative (19)
n = number: NS = not sigmficant, p = probability: Ref = reference
the mortality rate in patients with acute myocardial infarction
was generally higher than today. In the most recent well
designed trial of the European Cooperative Study Group
(19), low risk patients were excluded, which in part may
explain an overall mortality rate within 6 months of 30.6%
in the control group. The difference in the mortality rate up
to the 21st day was not statistically significant in this trial;
mortality rate was 11.5% in the group treated with strep-
tokinase and 17.6% in the control group .
Early treatment within 3 hours after onset of symptoms
was suggested as more favorable than later treatment (17,20);
however, a clear significance has never been demonstrated
(11). In the European Cooperative Study Group trial, only
two patients had been treated within 3 hours and about one-
third 3 to 5 hours after the onset of symptoms. There was
a consistent difference in the mortality rate of the two groups
that had received treatment within 12 hours after the sug-
gested beginning of myocardial infarction (19).
Limitations of studies. Although these results seemed
encouraging, for various reason s intravenous thrombolysis
did not become a generally accepted mode of therapy in
acute myocardial infarction (2 1,22). Because of erroneous
design , inaccurate technology or failure of appropri ate data
analysis, most of the earlier studies ( 11, 12) remained equiv-
ocal; however , the true impact of the European Cooperative
Study Group trial (19) was also disputed , mostly because
the mechani sm of the benefici al effect remained an unan-
swered major question. At the time , rapid lysis of thrombotic
coronary occlusion had not been proved and the suggestion
that an improvement in microc irculation through a reduction
in total peripheral resistance may limit the infarct size and
thus reduce mortalit y did not seem very attractive . It was
claimed that there were safer and more easily controlled
means of reducing afterload than by using a 12 to 24 hour
infusion of streptokinase with its bleeding hazards (22).
Recanalization Success Rate
Intracoronary streptokinase therapy. Recanalization
success rates between 64% (23) and more than 90% (5) have
been reported for intracoronary streptokinase infusion. These
results are difficult to judge , however, partly because an
attempt at mechanical recanalization was made , nitrogl y-
cerin or nifedipine was admini stered by intracoronary in-
jection and in some patients the occluded coronary artery
was opened by the intracoronary inject ion of contra st ma-
terial (24) . Recanalization of 276 (76%) of 361 totally oc-
cluded infarct arteries was reported in the European Re-
perfusion Registry (25). A special coronary infusion catheter,
advanced through the lumen of the angiography catheter to
a point 2 to 3 mm proximal to the site of coronary occlusion ,
may improve the succes s rate (5).
Apparently, the interval between the onset of symptoms
and the initiation of streptokinase therapy is of major im-
portance (26,27). Recent investigations by Lee et al. (28)
showed that when an intracoronary streptokinase infusion
was begun less than 5 hours after onset of symptoms, re-
canalization was achieved in 18 of 22 totally occluded infarct
vessels; however, recanalization was successful in only 13
patients (59%) within 1 hour after starting treatment. With
initiation of intracoronary streptokinase infusion 5 to 7 hours
after the onset of symptoms, a 1 hour success rate in 4
(37%) of 11 patient s was achieved.
Intravenous streptokinase therapy. With a 30 minute
intravenous infusion of 500 ,000 IV streptokinase, we could
angiographically prove reopening of 8 of 15 (6) or 11 of
21 (29) totally occluded coronary infarct vessels within 1
hour. These recanalization success rates refer to starting
treatment 3.8 ± 1.3 hours ( ± standard deviation) after
symptom onset. The success rate was significantly depen-
dent on the time interval from symptom onset to treatment.
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This may partly explain the higher efficacy reported with
intracoronary streptokinase infusion. All our patients re-
ceiving streptokinase within 3 hours after the onset of symp-
toms had restoration of coronary blood flow (30) .
Neuhaus et al. (31) demonstrated reopening of a totally
occluded coronary artery within 35 to 80 minutes in 24
(63%) of 38 patients by a 1 hour intravenous infusion of
approximately 1,500,000 IU streptokinase. In this study,
successful recanalization was also closely related to a shorter
interval from the onset of symptoms to initiation of strep-
tokinase therapy. On the average, infusion was initiated 3.2
hours after the onset of symptoms; there was a success rate
of 73% in patients treated within 3 hours after symptom
onset.
Without coronary angiography in the acute phase, we
recently studied the effects of an intravenous streptokinase
infusion in 50 patients with acute transmural myocardial
infarction by means of serial serum creatine kinase (CK-
MB) activity curves and angiography in the fourth week
(29). Nineteen patients received 500,000 IR streptokinase
within 30 minutes and 31 received 1,500,000 IV within I
hour. For comparative purposes , the angiographic findings
obtained approximately 8 weeks after the acute event in 52
patients without streptokinase or heparin treatment were
evaluated (Table 2) . In the group treated with streptokinase,
the involved coronary artery corresponding to the electro-
cardiographic location of myocardial injury was found pat-
ent in 84% as compared with 25% in the control group.
Furthermore, in contrast to the group treated with strep-
tokinase, the control group patients with nonoccluded infarct
vessels often had remaining subtotal arteriosclerotic obstruc-
tion with threadlike distal coronary patency only. Compa-
rable findings in patients without streptokinase treatment
were recently reported by Pichard et al. (32). Thus, spon-
taneous clot lysis with substantial persisting recanalization
does not occur for a period of at least 1 to 2 months after
transmural myocardial infarction. Patients without strepto-
kinase treatment had total occlusion of the infarct vessel 1
to 2 months after acute myocardial infarction at a similar
frequency as that in patients with evolving acute myocardial
infarction who presented for streptokinase therapy (26,29).
The high recanalization success rate as well as the im-
Table 2. Residual Mean DiameterStenosis of the Infarct-
Related Coronary Artery in Patients With and Without
Intravenous Streptokinase (SK) Therapy
Diameter Stenosis 4th Week , 3 to 13 Weeks.
of the Infarct Artery SK NQSK
< 55% 9 (18%) 1 (2%)
55 to 69% 20 (40%) 1 (2%)
~ 70% 13 (26%) II (21%)
Occluded 8 (16%) 39 (75%)
Total 50 52
portance of expeditious intravenous streptokinase infusion
are also demonstrated by the results listed in Table 3. Of a
total of75 patients, 6 with postintervention reinfarction were
excluded. In the remaining 69 patients , the infarct-related
coronary artery was found patent in the fourth week in all
36 patients in whom intravenous streptokinase infusion was
started within 3 hours after the onset of symptoms, and in
27 (82%) of 33 with initiation of treatment more than 3
hours after symptom onset (29).
Conclusion. Rapid restoration of coronary blood flow
is closely related to a shorter interval from symptom onset
to intravenous streptokinase infusion; however, ultimate clot
lysis most probably occurs as frequently with the intrave-
nous approach as with intracoronary application,
Thrombus Lysis Time
Intravenous streptokinase. It has been shown that lysis
of a coronary clot with the intravenous approach lasts, on
the average , 15 minutes longer than with intracoronary
streptokinase application (8 ,31) . The study by Neuhaus et
al. (8) , however, was not performed in a random fashion ;
thus the data obtained are not firmly conclusive . During an
observation period of 60 to 80 minutes, the rate of reca-
nalization with the intravenous approach was somewhat lower
than that reported for intracoronary streptokinase applica-
tion. As discussed previously, restoration of coronary blood
flow takes place in nearly all patients with acute myocardial
infarction treated with intravenous streptokinase infusion ,
but may occur with a delay of up to a few hours. Thus, the
difference in the total average lysis time between both modes
of streptokinase infusion may be more than 15 minutes .
Nevertheless, the delay in restoration of coronary blood flow
with the intravenous approach as compared with intracor-
onary streptokinase infusion may not be of decisive im-
portance , especially when considering that systemic strep-
tokinase infusion can be readily implemented early by the
primary care physician in the mobile coronary care unit or
even in the patient 's home (30). This results not only in
avoiding loss of time until angiography but also, because
of earlier initiation of treatment , in a shorter thrombus lysis
time. An early appearance of creatine kinase-MB in the
Table 3. Relation Between Beginning of Intravenous
Streptokinase Infusion Within 3 Hours or More
After Onset of Symptoms and Patency of the InfarctCoronary
Artery in the Fourth Week (69 patients without post-
intervention reinfarction)
:s 3 h > 3 h Total
Patent 36 27 63
Occluded 0 6 6
Total 36 33 69
Risk 0% 18.2%
Chi-square X' = 7.17. P < 0.01
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systemic circulation and a premature peak in the serial serum
enzyme curve together with rapid electrocardiographic changes
strongly suggest that in the majorit y of these patients, res-
toration of coronary blood flow is achie ved within 1 to 2
hours after beginning the intravenous streptokinase infusion
(30).
Combined intravenous and intracoronary streptoki-
nase. Most rapid recanalization after onset of symptoms
can probabl y be achieved by a combination of both modes
of streptokinase application (29) . With an initial 20 minute
intravenous infusion of 200,000 IU streptokinase , the re-
canalization success rate durin g a subsequent intracoronary
streptokinase application could be improved from 81 to 91%
and the thrombus lysis time from the beginning of the in-
tracoronary application shortened from 35 ± 19 to 18 ±
9 minutes (33) . Similarly , immediate institution of an in-
travenou s infusion of 30,000 IU streptokinase/min resulted
in a patent artery in 45% of patients on angiography 30 to
60 minutes later; the additional intracoron ary streptokinase
application led to a rapid recan alization in more than 80%
of the patients (34).
Conclusion. Thrombus lysis time lasts longer with in-
travenous streptokinase infusion as compared with intra-
coronary application; however the difference may be of
minor importance in the usual clin ical setting of acute myo-
cardial infarction.
Patients With Subtotal Occlusion
Objections against intravenou s streptokinase treatment
without angiography in the acute phase are based on the
concern that patients will be treated who do not have com-
plete coronary artery occlusion . DeWood et a1. (l) observed
patent coronary arteries in only 13% of the patients studied
with angiography within 4 hours but in 32% of the patient s
6 to 12 hours after the onset of symptoms, suggesting some
spontaneous recanalization after the very early hours of
evolving myocardial infarction . However, most of the patent
arteries remained so highly obstructed that it is questionable
if there was sufficient nutritional flow. According to our
experience , these patients may benefit most from restoration
of a sufficient coronary flow when intravenous streptokinase
infusion dissolves the threatening coronary thrombus. In
four patients, we found an increase in ejection fraction from
49.5 ± 12.3% before intervention to 60. 6 ± 0.4 % in the
fourth week while the systolic segmental shortening of the
ischem ic area improved from 5.9 ± 9.3 to 26.7 ± 7.7%
(30). On videodensitometry , an improved coronary flow
could be demonstrated after intravenous streptokinase in-
fusion (35) . The presence of nonoccluding coronary throm-
bus in unstable myocardial ischemic syndrome (36) that can
progress to total occlusion and myocardial infarction is con-
sistent with the potential spectrum of propagating thrombu s
extending to occluding thrombosis in acute myocardial in-
farct ion . Neill et a1. (37) have shown that approximately
one-third of patients with intermediate coronary syndrome
exhibit late total occlu sion of a previously highly stenotic
lesion , frequently with associated myocardial infarction. In
patient s with unstabl e angina pectori s, it was shown that
intravenous streptokinase infusion can prevent progre ssion
to myocardial infarction (38).
Conclusion. Different mechan isms are involved in pa-
tients with acute myocardial infarction but incomplete oc-
clusion of the infarct-related artery . Nonoccluding throm-
bosis is most probabl y a major component. These patients
may benefit most from immediate intravenous streptokinase
infusion .
Reocclusion Rate and Need f or Additional
Surgical Intervention
In the majority of cases, a significant arteriosclerotic
stenosis at the site of the previous thrombotic occlusion
remains after successful streptokinase treatment. Thu s, it
can be assumed that the affected coronary artery continues
to pose the same hazard after streptokinase- induced resto-
ration of coronary blood flow that it posed before throm-
bolytic occlusion. Therefore , early mechanical interventions
such as coronary artery bypass grafting and percutaneous
transluminal coronary angioplasty have been performed in
suitable patients (39-41); however, the necessity and effi-
cacy of such additional interventions rema in to be deter-
mined. The finding that improvement in ventricular function
was independent of whether the bypass graft circumvent ing
the residual fixed arteriosclerotic stenosis in the infarct ves-
sel was patent or not may indicate that early reperfu sion
achieved by the streptokinase-indu ced recanalization alone
was sufficient to restore considerable myocardial function
in evolving myocardial infarction (39).
Reinfarction and late reocclusion rate. Although a high
incidence rate of reinfarction (2 1%) and late hospital reoc -
elusion (8%) has been reported after successful intracoron-
ary streptokinase treatment (42), this is not the general
experience . Evidence was provided (5) that continued in-
tracoronary streptokinase infusion for at least 60 minutes
after the artery had become patent substantially lowers the
incidence of reocclu sion. Furthermore, late reocclu sion is
usually either not associated with reinfarction or the clinical
course of reinfarction is mild and the corresponding increa se
in the CK-MB serum activity is small, possibly becau se of
interim development of improved collateral circulation
(30,43).
With the intravenous approach , the reocclusion or rein-
farction rate, or both , was less than 10% (29,31). Rutsch
(33) observed a decrease in reinfarction rate from 13 to 7%
since intracoronary streptokinase application was preced ed
by an intravenous streptokinase infusion (33). However ,
probably more important for preventing reinfarction is proper
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poststreptokinase anticoagulation with a total dose of hep-
arin of more than 20,000 IU/day for at least 3 to 5 days,
replaced by phenprocoumon or warfarin thereafter.
Indications for additional intervention. The decision
if and in which patient additional mechanical intervention
should be undertaken can be made without angiography
preceding the streptokinase treatment. After early intrave-
nous streptokinase infusion, coronary angiography can be
performed on an elective basis and in relation to the clinical
course. Even immediately after or during intravenous strep-
tokinase infusion, angiography can be performed safely
(33,34). For an early surgical intervention systemic throm-
bolytic activity could be stopped with epsilon-amino-cap-
ronic acid and aprotenin.
Conclusion. Performance of intravenous streptokinase
infusion without preceding angiography in patients with acute
myocardial infarction does not limit the possibility of ap-
plying appropriately subsequent surgical or mechanical
intervention.
Salvage of Ischemic Myocardium
Assessment of left ventricular function by means of re-
peated angiography (24,44), cardiac gated blood pool im-
aging (45) or thallium-201 studies (46-48) revealed en-
hanced global and regional left ventricular performance
compared with prestreptokinase left ventricular function in
patients with recanalization of an occluded infarct artery,
whereas such improvement was absent in nonrecanalized
patients. The same results were found in patients treated
with a high dose intravenous short-time infusion of strep-
tokinase (7,31). In patients with reopening of the involved
coronary artery, systolic segmental shortening improved
significantly from 7.0 ± 4.9 before intervention to 20.1 ±
10.3 in the fourth week after acute myocardial infarction
(30).
Ventricular wall motion studies after intravenous
streptokinase. Recently, we studied regional left ventric-
ular wall motion abnormalities in patients who had received
an intravenous streptokinase infusion without angiography
in the acute phase using angiography in the fourth week
(29). Patients with previous infarction or postintervention
reinfarction were excluded. There was a significant inverse
correlation between the percent of segmental systolic short-
ening of the infarcted area and time interval from symptom
onset to treatment; that is, the infarct size calculated in the
fourth week significantly depended on treatment delay (Fig.
1). Segmental area shortening of 10% or less was defined
as akinetic. Patients treated within 3 hours after the onset
of symptoms exhibited significantly less akinesia than did
patients with initiation of intravenous streptokinase infusion
3 to 6 hours after the onset of symptoms (Table 4). These
data again strongly suggest that at least in those patients
treated early, jeopardized myocardium was preserved by
Table 4. Relation Between Beginning of Intravenous
Streptokinase (SK) Infusion Within 3 Hours or More Than 3
Hours After Symptom Onset and Findings of Akinetic Segments
of the Left Ventricular Wall in the Fourth Week (34 patients
without previous infarction or postintervention reinfarction)
:s 3 h > 3 h Total
No akinesia 11 4 15
Akinesia 6 13 19
Total 17 17 34
Risk 35.3% 76.4%
Chi-square (x') = 5.85; P < 005.
early restoration of coronary blood flow during the acute
stage of myocardial infarction.
Conclusion. Patients with acute myocardial infarction
may benefit from an intracoronary as well as an intravenous
streptokinase infusion. The efficacy of both modes of in-
tervention on myocardial salvage and restoration of func-
tion, however, has not been evaluated objectively because
of lack of an untreated randomized control group in all
studies.
Side Effects
Streptokinase therapy. With preceding intravenous in-
jection of corticosteroids, no serious pyretic or allergic re-
action attributable to streptokinase occurred. With an intra-
venous short-time infusion of 500,000 to 1,500,000 IU
streptokinase in more than 100 patients, there were no se-
rious bleeding complications, although serum fibrinogen
concentrations declined below 1 giliter over a period of 27
hours (29,31). Systemic fibrinolytic activity with major de-
crease of fibrinogen concentration is also common with in-
tracoronary streptokinase infusion. In 204 patients treated
with intracoronary streptokinase infusion in four German
clinics, the incidence of serious systemic hemorrhagic com-
plications requiring blood transfusion was 7.4% (42). In-
tracerebral hemorrhage occurred in one patient who died of
cardiogenic shock (26).
Cardiac catheterization. Coronary angiography, a pre-
requisite for intracoronary streptokinase application, is not
without its complication in the setting of acute myocardial
infarction. DeWood et al. (1) quoted a 9.3% rate of ven-
tricular fibrillation. During catheterization and attempted
recanalization of an occluded artery, ventricular fibrillation
in 7 of 41 patients has been reported (24). In the study of
Serruys et al. (23), 5 of 83 patients died during the cathe-
terization procedure, 2 of them because of migration of
thrombotic material. Of the 62 surviving patients, 21 had
complications that required treatment. Complications such
as ventricular tachyarrhythmias or substantial decrease in
arterial blood pressure may cause additional damage to jeop-
ardized ischemic myocardium.
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Conclusion. With both modes of streptokinase treat-
ment, the incidence of serious systemic hemorrhagic com-
plications seems to be low. Cardiac catheterization in acute
myocardial infarction bears some risk.
General Conclusions
High dose intravenous short-time infusion of streptoki-
nase can be performed safely in patients with evolving myo-
cardial infarction. In the majority of cases, patency of coro-
nary occlusion can be reestablished, or in thrombotically
subtotal occlusion sufficient coronary blood flow can be
restored. Preliminary experience suggests a beneficial effect
on left ventricular function and ultimate infarct size.
Even though an absolute deadline for effective reperfu-
sion may not be predicted in the individual case, it can be
assumed that maximal benefit will be obtained by the earliest
possible restoration of sufficient coronary blood flow. In
comparison with intracoronary streptokinase application,
coronary thrombus lysis time lasts somewhat longer with
the intravenous approach. However, this may be balanced,
at least in part, by a shorter delay when treatment is instituted
without preceding coronary angiography. If immediate in-
tracoronary streptokinase infusion cannot be performed, a
high dose, short-time intravenous infusion of streptokinase
appears to be the appropriate alternative. Of note is the
European Cooperative Study Group trial (19), demonstrat-
ing a significantly lower 6 month mortality in patients treated
with an intravenous streptokinase infusion up to 12 hours
after the beginning of acute myocardial infarction. Of further
note is the finding of improvement in left ventricular func-
tion in patients recanalized by intracoronary streptokinase
infusion more than 8 hours after symptom onset (44,45).
To ascertain the true impact of either intracoronary or in-
travenous streptokinase infusion on short- or long-term mor-
bidity and mortality consequential to acute myocardial in-
farction, conclusive randomized trials are needed (25).
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